Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 3c; Cuts FY14 Outlook

Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.24, $0.03 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $50.13 million versus the consensus estimate of $52.18 million.

Meridian Bioscience, Inc. sees FY2014 EPS of $0.85-$0.90, versus prior guidance of $0.98-$1.03 and the consensus of $0.97. Meridian Bioscience, Inc. sees FY2014 revenue of $190-195 million, versus prior guidance of $203-208 million and the consensus of $201.05 million.

For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance